-
Important news
-
News
-
Shenzhen
-
China
-
World
-
Opinion
-
Sports
-
Kaleidoscope
-
Photos
-
Business
-
Markets
-
Business/Markets
-
World Economy
-
Speak Shenzhen
-
Leisure
-
Culture
-
Travel
-
Entertainment
-
Digital Paper
-
In-Depth
-
Weekend
-
Lifestyle
-
Diversions
-
Movies
-
Hotels and Food
-
Special Report
-
Yes Teens!
-
News Picks
-
Tech and Science
-
Glamour
-
Campus
-
Budding Writers
-
Fun
-
Futian Today
-
Advertorial
-
CHTF Special
-
Focus
-
Guide
-
Nanshan
-
Hit Bravo
-
People
-
Person of the week
-
Majors Forum
-
Shopping
-
Investment
-
Tech and Vogue
-
Junior Journalist Program
-
Currency Focus
-
Food and Drink
-
Restaurants
-
Yearend Review
-
QINGDAO TODAY
在线翻译:
szdaily -> Special Report -> 
‘Therapeutic’ game for ADHD
    2020-06-18  08:53    Shenzhen Daily

U.S. health officials have approved the first game-based treatment for children with attention deficit hyperactivity disorder, part of a trend toward “digital therapeutics” or software to address certain conditions.

The Food and Drug Administration said Monday it approved the sale by prescription of the game EndeavorRX from health tech startup Akili Interactive for children aged 8-12 who have been diagnosed with ADHD.

The FDA said this was the first digital therapeutic intended to treat ADHD, as well as the first game-based therapeutic approved for any type of condition.

The game, designed to improve cognitive function, is designed as part of a program that may also include other kinds of therapy, medication, and educational programs.

“The EndeavorRx device offers a non-drug option for improving symptoms associated with ADHD in children and is an important example of the growing field of digital therapy and digital therapeutics,” said Jeffrey Shuren, director of the FDA Center for Devices and Radiological Health.

EndeavorRX allows children to control cartoon-like characters on a type of hoverboard and is designed to target and activate neural systems through sensory stimuli and motor challenges to improve cognitive functioning.

The approval of EndeavorRx followed studies of some 600 children diagnosed with ADHD.

The company said the research found that after four weeks of EndeavorRx treatment, one-third of children no longer had a measurable attention deficit on at least one measure of objective attention.

(SD-Agencies)

深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010-2020, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@126.com